RT Journal Article
SR Electronic
T1 Prognosis and hematological findings in patients with COVID-19 in an Amazonian population of Peru
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.31.21250859
DO 10.1101/2021.01.31.21250859
A1 Iglesias-Osores, Sebastian
A1 Rafael-Heredia, Arturo
A1 Rojas-Tello, Eric Ricardo
A1 Ortiz-Uribe, Washington A.
A1 Román, Leveau-Bartra Walter
A1 Armando, Leveau-Bartra Orison
A1 Miguel, Alcántara-Mimbela
A1 Córdova-Rojas, Lizbeth M.
A1 López-López, Elmer
A1 Failoc-Rojas, Virgilio E.
YR 2021
UL http://medrxiv.org/content/early/2021/02/01/2021.01.31.21250859.abstract
AB Objective This study examined the laboratory results of COVID-19 patients from a hospital in the Peruvian Amazon and their clinical prognosis.Methods An analytical cross-sectional study was carried out whose purpose was to identify the laboratory tests of patients with COVID-19 and mortality in a hospital in Ucayali, Peru during the period from March 13 to May 9, 2020, selecting a total of 127 with Covid-19. Mean and the standard deviation was described for age, leukocytes, neutrophils, platelets, RDW-SD; median and interquartile range for the variables lymphocyte, RN / L, fibrinogen, CRP, D-dimer, DHL, hematocrit, monocytes, eosinophils.Results No differences were observed in this population regarding death and sex (OR: 1.31; 95% CI 0.92 to 1.87), however, it was observed that, for each one-year increase, the probability of death increased by 4% (PR: 1.04, 95% CI 1.03 to 1.05). The IRR (Incidence Risk Ratio) analysis for the numerical variables showed results strongly associated with hematological values such as Leukocytes (scaled by 2500 units) (IRR: 1.08, 95% CI 1.03 to 1.13), neutrophils (scaled by 2500 units) (IRR: 1.08; 95% CI 1.03 to 1.13), on the contrary, it is observed that the increase of 1000 units in lymphocytes, the probability of dying decreased by 48% (IRR: 0.52; 95% CI 0.38 to 071).Conclusion Parameters such as leukocytes and neutrophils were statistically much higher in patients who died.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research has been approved by the Ethics Committee of the National University of Ucayali. Codes were used to maintain the confidentiality of data for COVID-19 patients eligible for this study. The ethical principles of the Declaration of Helsinki were respected.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe information is clinical data that should not be disclosed. https://doi.org/10.6084/m9.figshare.13670275.v2